CA2517274C - Methodes et compositions permettant de traiter un cancer et une maladie infectieuse a l'aide de complexes d'alpha (2) macroglobulines moleculaires antigenes - Google Patents

Methodes et compositions permettant de traiter un cancer et une maladie infectieuse a l'aide de complexes d'alpha (2) macroglobulines moleculaires antigenes Download PDF

Info

Publication number
CA2517274C
CA2517274C CA2517274A CA2517274A CA2517274C CA 2517274 C CA2517274 C CA 2517274C CA 2517274 A CA2517274 A CA 2517274A CA 2517274 A CA2517274 A CA 2517274A CA 2517274 C CA2517274 C CA 2517274C
Authority
CA
Canada
Prior art keywords
complexes
alpha
macroglobulin
cancer
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2517274A
Other languages
English (en)
Other versions
CA2517274A1 (fr
Inventor
Pramod K. Srivastava
Robert J. Binder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut Health Center
Original Assignee
University of Connecticut Health Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut Health Center filed Critical University of Connecticut Health Center
Publication of CA2517274A1 publication Critical patent/CA2517274A1/fr
Application granted granted Critical
Publication of CA2517274C publication Critical patent/CA2517274C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne l'utilisation de complexes d'alpha (2) macroglobulines isolés à partir du sérum d'un mammifère. L'invention concerne également des procédés permettant de produire ces complexes et des compositions comprenant les complexes d'alpha (2) macroglobulines isolés à partir du sérum d'un mammifère, ces compositions étant utilisées dans des méthodes permettant de traiter ou de prévenir un cancer ou une maladie infectieuse. L'invention concerne en outre des méthodes permettant de traiter ou de prévenir un cancer ou une maladie infectieuse à l'aide des complexes isolés à partir du sérum d'un mammifère. L'invention concerne enfin des procédés de production de complexes d'alpha (2) macroglobulines.
CA2517274A 2003-02-27 2003-03-05 Methodes et compositions permettant de traiter un cancer et une maladie infectieuse a l'aide de complexes d'alpha (2) macroglobulines moleculaires antigenes Expired - Fee Related CA2517274C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45075103P 2003-02-27 2003-02-27
US60/450,751 2003-02-27
PCT/US2003/006625 WO2004078921A2 (fr) 2003-02-27 2003-03-05 Methodes et compositions permettant de traiter un cancer et une maladie infectieuse a l'aide de complexes d'alpha (2) macroglobulines moleculaires antigenes

Publications (2)

Publication Number Publication Date
CA2517274A1 CA2517274A1 (fr) 2004-09-16
CA2517274C true CA2517274C (fr) 2012-09-18

Family

ID=32962526

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2517274A Expired - Fee Related CA2517274C (fr) 2003-02-27 2003-03-05 Methodes et compositions permettant de traiter un cancer et une maladie infectieuse a l'aide de complexes d'alpha (2) macroglobulines moleculaires antigenes

Country Status (3)

Country Link
AU (1) AU2003225661A1 (fr)
CA (1) CA2517274C (fr)
WO (1) WO2004078921A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004030541D1 (de) 2003-02-20 2011-01-27 Univ Connecticut Health Ct Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
EP2257301B1 (fr) 2008-03-03 2014-01-22 The University of Miami Immunothérapie à base de cellules cancéreuses allogéniques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179462B2 (en) * 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
AU2001292674A1 (en) * 2000-09-15 2002-04-29 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes

Also Published As

Publication number Publication date
WO2004078921A3 (fr) 2004-12-29
AU2003225661A8 (en) 2004-09-28
AU2003225661A1 (en) 2004-09-28
CA2517274A1 (fr) 2004-09-16
WO2004078921A2 (fr) 2004-09-16

Similar Documents

Publication Publication Date Title
US9566348B2 (en) Methods and compositions for the treatment of cancer and infectious disease using alpha(2) macroglobulin-antigenic molecule complexes
EP1603936B1 (fr) Utilisation de lectines en vue de promouvoir l'oligomerisation des glycoproteines et des molecules antigeniques
US20040253228A1 (en) Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease
WO2005120558A2 (fr) Procede pour la fabrication de compositions comportant des proteines de choc thermique ou de l'alpha-2-macroglobuline pour le traitement du cancer et de maladie infectieuse
US20100297061A1 (en) Stat3 antagonists and their uses as vaccines against cancer
US20050084490A1 (en) Boroproline compound combination therapy
US20050221395A1 (en) Methods and products based on oligomerization of stress proteins
US20220160464A1 (en) Smart composite with antibiofilm, mineralizing, and antiinfection therapeutic effects
AU2005218638A1 (en) Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
WO2004078921A2 (fr) Methodes et compositions permettant de traiter un cancer et une maladie infectieuse a l'aide de complexes d'alpha (2) macroglobulines moleculaires antigenes
CN1942199A (zh) 使用α(2)巨球蛋白－抗原分子复合物治疗癌症和传染病的方法和组合物

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180305